Literature DB >> 30565721

Somatic genetic alterations in synchronous and metachronous low-grade serous tumours and high-grade carcinomas of the adnexa.

Rajmohan Murali1, Pier Selenica1, David N Brown1, R Keira Cheetham2, Raghu Chandramohan1, Nidia L Claros3, Nancy Bouvier3, Donavan T Cheng4, Robert A Soslow1, Britta Weigelt1, W Glenn McCluggage5.   

Abstract

AIMS: Low-grade serous carcinomas (LGSCs) and their precursors serous borderline tumours (SBTs) characteristically harbour mutations in BRAF, KRAS or NRAS but rarely in TP53, whereas high-grade serous carcinomas (HGSCs) are characterised by frequent TP53 mutations but rare BRAF, KRAS or NRAS mutations. In a small subset of cases, LGSCs and/or SBTs develop into high-grade tumours, including HGSCs and poorly differentiated carcinomas (PDCs). Here, we sought to define the repertoire of somatic genetic alterations in low-grade serous tumours and synchronous or metachronous high-grade adnexal carcinomas. METHODS AND
RESULTS: DNA extracted from five SBTs/LGSCs and synchronous or metachronous HGSCs/PDCs and matched normal tissue was subjected to massively parallel sequencing targeting all exons and selected non-coding regions of 341 cancer-related genes. The low-grade and high-grade tumours from a given case were related, and shared mutations and copy number alterations. Progression from low-grade to high-grade lesions was observed, and involved the acquisition of additional mutations and/or copy number alterations, or shifts from subclonal to clonal mutations. Only two (an HGSC and a PDC) of the five high-grade tumours investigated harboured TP53 mutations, whereas NRAS and KRAS hotspot mutations were seen in two HGSCs and one HGSC, respectively.
CONCLUSIONS: Our results suggest that progression from SBT to HGSC may take place in a subset of cases, and that at least some of the rare HGSCs lacking TP53 mutations may be derived from a low-grade serous precursor.
© 2018 John Wiley & Sons Ltd.

Entities:  

Keywords:  high-grade serous carcinoma; low-grade serous carcinoma; massively parallel sequencing; molecular genetics; ovary; serous borderline tumour; tumour progression

Mesh:

Substances:

Year:  2019        PMID: 30565721      PMCID: PMC6626549          DOI: 10.1111/his.13796

Source DB:  PubMed          Journal:  Histopathology        ISSN: 0309-0167            Impact factor:   5.087


  63 in total

1.  A candidate precursor to serous carcinoma that originates in the distal fallopian tube.

Authors:  Y Lee; A Miron; R Drapkin; M R Nucci; F Medeiros; A Saleemuddin; J Garber; C Birch; H Mou; R W Gordon; D W Cramer; F D McKeon; C P Crum
Journal:  J Pathol       Date:  2007-01       Impact factor: 7.996

2.  Carcinoma of the ovary. FIGO 26th Annual Report on the Results of Treatment in Gynecological Cancer.

Authors:  A P M Heintz; F Odicino; P Maisonneuve; M A Quinn; J L Benedet; W T Creasman; H Y S Ngan; S Pecorelli; U Beller
Journal:  Int J Gynaecol Obstet       Date:  2006-11       Impact factor: 3.561

3.  Sarcomatoid carcinoma arising within a serous borderline ovarian tumour: a case report and practical approach to differential diagnosis.

Authors:  T D Andrews; P M Dutton; G Beattie; A Al-Nafussi
Journal:  Histopathology       Date:  2007-09-28       Impact factor: 5.087

4.  Geographical variations in TP53 mutational spectrum in ovarian carcinomas.

Authors:  A Dansonka-Mieszkowska; A H Ludwig; E Kraszewska; J Kupryjańczyk
Journal:  Ann Hum Genet       Date:  2006-09       Impact factor: 1.670

5.  Grading ovarian serous carcinoma using a two-tier system.

Authors:  Anais Malpica; Michael T Deavers; Karen Lu; Diane C Bodurka; Edward N Atkinson; David M Gershenson; Elvio G Silva
Journal:  Am J Surg Pathol       Date:  2004-04       Impact factor: 6.394

Review 6.  Ovarian tumorigenesis: a proposed model based on morphological and molecular genetic analysis.

Authors:  Ie-Ming Shih; Robert J Kurman
Journal:  Am J Pathol       Date:  2004-05       Impact factor: 4.307

7.  The development of high-grade serous carcinoma from atypical proliferative (borderline) serous tumors and low-grade micropapillary serous carcinoma: a morphologic and molecular genetic analysis.

Authors:  Reiko Dehari; Robert J Kurman; Sanjay Logani; Ie-Ming Shih
Journal:  Am J Surg Pathol       Date:  2007-07       Impact factor: 6.394

Review 8.  Pathogenesis of ovarian cancer: lessons from morphology and molecular biology and their clinical implications.

Authors:  Robert J Kurman; Ie-Ming Shih
Journal:  Int J Gynecol Pathol       Date:  2008-04       Impact factor: 2.762

9.  Early recurrence of ovarian serous borderline tumor as high-grade carcinoma: a report of two cases.

Authors:  Robin L Parker; Philip B Clement; David J Chercover; Thangaraja Sornarajah; C Blake Gilks
Journal:  Int J Gynecol Pathol       Date:  2004-07       Impact factor: 2.762

10.  The COSMIC (Catalogue of Somatic Mutations in Cancer) database and website.

Authors:  S Bamford; E Dawson; S Forbes; J Clements; R Pettett; A Dogan; A Flanagan; J Teague; P A Futreal; M R Stratton; R Wooster
Journal:  Br J Cancer       Date:  2004-07-19       Impact factor: 7.640

View more
  3 in total

1.  Clinicopathologic and Molecular Features of Paired Cases of Metachronous Ovarian Serous Borderline Tumor and Subsequent Serous Carcinoma.

Authors:  Michael Herman Chui; Deyin Xing; Felix Zeppernick; Zoe Q Wang; Charlotte G Hannibal; Kirsten Frederiksen; Susanne K Kjaer; Leslie Cope; Robert J Kurman; Ie-Ming Shih; Tian-Li Wang; Russell Vang
Journal:  Am J Surg Pathol       Date:  2019-11       Impact factor: 6.394

2.  Low-grade serous carcinoma with extensive osseous metaplasia arising from ovarian serous cystadenofibroma.

Authors:  Renan Ribeiro E Ribeiro; Ashley Valenzuela; Lindsey Beffa; C James Sung; M Ruhul Quddus
Journal:  Gynecol Oncol Rep       Date:  2021-01-22

3.  Genomic profiling of primary and recurrent adult granulosa cell tumors of the ovary.

Authors:  Arnaud Da Cruz Paula; Edaise M da Silva; Sheila E Segura; Fresia Pareja; Rui Bi; Pier Selenica; Sarah H Kim; Lorenzo Ferrando; Mahsa Vahdatinia; Robert A Soslow; August Vidal; Sonia Gatius; Christopher G Przybycin; Nadeem R Abu-Rustum; Xavier Matias-Guiu; Brian P Rubin; Jorge S Reis-Filho; Deborah F DeLair; Britta Weigelt
Journal:  Mod Pathol       Date:  2020-03-12       Impact factor: 7.842

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.